title: A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice.
abstract: OBJECTIVE
  Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkappaB inhibitor reduces atherosclerosis.
  
  
  METHODS
  Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-alpha and adiponectin were also measured.
  
  
  RESULTS
  The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin.
  
  
  CONCLUSIONS
  A new NFkappaB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.
authors.affiliation: Geriatrics and Vascular Medicine, Tokyo Medical and Dental University Graduate School, Japan.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Chiba
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kondo
authors.forename: Shohei
authors.initials: S
authors.lastname: Shinozaki
authors.forename: Eiji
authors.initials: E
authors.lastname: Kaneko
authors.forename: Akihito
authors.initials: A
authors.lastname: Ishigami
authors.forename: Naoki
authors.initials: N
authors.lastname: Maruyama
authors.forename: Kazuo
authors.initials: K
authors.lastname: Umezawa
authors.forename: Kentaro
authors.initials: K
authors.lastname: Shimokado
mesh_terms: D052242:Adiponectin / Q000097:blood; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency* / Q000378:metabolism; D050197:Atherosclerosis / Q000188:drug therapy*; D001549:Benzamides / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003512:Cyclohexanones / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D052242:Adiponectin; D001057:Apolipoproteins E; D001549:Benzamides; D003512:Cyclohexanones; D016328:NF-kappa B; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; C464444:dehydroxymethylepoxyquinomicin; D002784:Cholesterol